Clearpoint Neuro (CLPT) investor relations material

Executive summary

• Ended 2025 with the strongest quarter, achieving record Q4 revenue of $10.4M (up 34% year-over-year) and full-year revenue of $37.0M (up 18%), driven by the IRRAS acquisition and robust momentum for 2026.

• Built a foundation with four product categories, over 60 biopharma partners, and more than 25 active clinical trials.

• Completed the acquisition of IRRAS Holdings, Inc. in November 2025, expanding into neurocritical care and broadening the product portfolio.

• Secured $20M in additional funding and ended 2025 with $45.9M in cash and equivalents.

• Showcased a prototype robotic neuro-navigation system and received EU MDR certification for navigation software.

Financial highlights

• 2025 total revenue was $37.0M, up from $31.4M in 2024, including $1.2M from IRRAS; Q4 2025 revenue was $10.4M, up from $7.8M in Q4 2024.

• Biologics and Drug Delivery revenue rose 10% to $19.0M in 2025; Neurosurgery Navigation revenue grew 44% to $14.8M, including IRRAS.

• Capital Equipment and Software revenue declined 18% to $3.1M in 2025; Q4 2025 revenue $0.5M, slightly down year-over-year.

• Gross margin for 2025 was 61%; Q4 2025 gross margin was 62%.

• Cash and equivalents at year-end 2025 were $45.9M, up from $20.1M at end of 2024.

Outlook and guidance

• 2026 revenue guidance set at $52M–$56M, driven by double-digit growth in all four product lines, excluding meaningful commercial drug delivery revenue.

• All four main product segments expected to grow double digits in 2026.

• Guidance reflects cautious assumptions due to FDA's more rigorous requirements for rare disease therapies and IRRAS integration priorities.

• Organic and inorganic growth expected to be balanced, with both contributing double-digit increases.

• Long-term target: 15–20% annual growth to reach $200M revenue by capturing 20% of a $1B market.